Abstract
Ischemic brain injury can be anticipated in a number of clinical settings such as procedures associated with a high-risk for stroke, patients with transient ischemic attacks or minor strokes who are at substantial risk for early recurrence and patients with multiple vascular risk factors with an enhanced risk for ischemic stroke over many years. In such high-risk settings, it may be possible to employ neuroprotective drugs prophylactically to reduce the extent and clinical consequences of ischemic events. The concept of prophylactic neuroprotection can be envisioned for varying time periods and with a variety of drug classes depending upon the target population. This review will focus on which target populations should be considered for prophylactic neuroprotection trials and which drugs might be used in such trials.
Keywords: Neuroprotection, prophylactic, statins, infarct, stroke
Current Drug Targets
Title: Prophylactic Neuroprotection
Volume: 8 Issue: 7
Author(s): Sean I. Savitz and Marc Fisher
Affiliation:
Keywords: Neuroprotection, prophylactic, statins, infarct, stroke
Abstract: Ischemic brain injury can be anticipated in a number of clinical settings such as procedures associated with a high-risk for stroke, patients with transient ischemic attacks or minor strokes who are at substantial risk for early recurrence and patients with multiple vascular risk factors with an enhanced risk for ischemic stroke over many years. In such high-risk settings, it may be possible to employ neuroprotective drugs prophylactically to reduce the extent and clinical consequences of ischemic events. The concept of prophylactic neuroprotection can be envisioned for varying time periods and with a variety of drug classes depending upon the target population. This review will focus on which target populations should be considered for prophylactic neuroprotection trials and which drugs might be used in such trials.
Export Options
About this article
Cite this article as:
Sean I. Savitz and Marc Fisher , Prophylactic Neuroprotection, Current Drug Targets 2007; 8 (7) . https://dx.doi.org/10.2174/138945007781077382
DOI https://dx.doi.org/10.2174/138945007781077382 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
Current Drug Targets Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Consequences of Elevated Homocysteine During Embryonic Development and Possible Modes of Action
Current Pharmaceutical Design Role of Neuronal Guidance Cues in the Pathophysiology of Obesity: A Peripheral and Central Overview
Current Pharmaceutical Design Perspectives on the Development of Antioxidant Antiepileptogenic Agents
Mini-Reviews in Medicinal Chemistry Wnt/β-Catenin Signaling in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets The Multiple Aspects of Stroke and Stem Cell Therapy
Current Molecular Medicine Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry MMP-9 Inhibitors in the Brain: Can Old Bullets Shoot New Targets?
Current Pharmaceutical Design Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Recent Patents on Anti-Cancer Drug Discovery Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration
Current Drug Targets Effect of Particle Formulation on Dry Powder Inhalation Efficiency
Current Pharmaceutical Design Pharmacological Approach of No-Reflow Phenomenon Related with Percutaneous Coronary Interventions
Cardiovascular & Hematological Agents in Medicinal Chemistry Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Current Drug Targets NMDA Receptors are not Alone: Dynamic Regulation of NMDA Receptor Structure and Function by Neuregulins and Transient Cholesterol-Rich Membrane Domains Leads to Disease-Specific Nuances of Glutamate- Signalling
Current Topics in Medicinal Chemistry Calcium Channel Blockers in the Management of Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Autocrine and Paracrine Secretion of Vascular Endothelial Growth Factor in the Pre-Hypoxic Diabetic Retina
Current Diabetes Reviews